SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Nebius Group is trending as investors react to a massive $27 billion AI infrastructure deal with Meta, which significantly bolsters the company's long-term contracted backlog. While the community is debating the impact of a new $3.75 billion convertible debt offering intended to fund this rapid expansion, many remain bullish on the stock's long-term potential due to sustained backing from industry giants like NVIDIA and Microsoft.

Oklo, Inc. engages in the development of fission reactors. It provides clean energy through the design and deployment of fast fission power plants. The company was founded by Jacob DeWitte and Caroline Cochran on July 3, 2013 and is headquartered in Santa Clara, CA.

Oklo Inc. - Ordinary Shares - Class A

Oklo Inc.

Oklo Inc. is experiencing heightened volatility and trading volume as investors position themselves ahead of the upcoming fourth-quarter earnings release and monitor key regulatory milestones. The community is actively debating the company's long-term potential as a provider of nuclear energy for AI data centers versus concerns regarding its pre-revenue status, recent insider selling, and the broader macro-driven rotation out of high-beta speculative equities.

Swarmer, Inc. is an AI-driven software company, which develops software platforms and AI systems for autonomous swarm control of drones and unmanned vehicles. The firm offers STYX AI Command and Control System, MINAS Autonomy and Collaboration AI, and TRIDENT Embedded Drone Operating System. The company was founded by Alex Fink and Serhii Kuprienko in May 2023 and is headquartered in Austin, TX.

Swarmer Inc.

Swarmer Inc. is drawing significant attention following its Nasdaq IPO and volatile market debut, with investors debating the growth potential of its drone autonomy software currently deployed in combat zones.

POET Technologies, Inc. engages in the designing, developing, manufacturing and sale of opto-electronic solutions for the sensing, data communications and telecommunications markets. It developed POET Optical Interposer platform, which allows the integration of electronic and photonic devices into a single multi-chip module. The company was founded on November 14, 1985 and is headquartered in Toronto, Canada.

POET Technologies Inc

POET Technologies is seeing a surge in investor interest and heavy trading volume ahead of the upcoming Optical Fiber Communications Conference (OFC), as market participants speculate on potential major partnership announcements and purchase orders. Community sentiment remains polarized between long-term investors tracking institutional accumulation and technical alignment with hyperscale AI hardware, and skeptics voicing concerns over persistent pre-revenue status and reliance on strategic collaborations.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is experiencing heightened volatility and investor attention following positive Phase 3 clinical data for its Retevmo therapy and reports that the company has built significant inventory ahead of a potential April FDA decision on its oral obesity pill. Meanwhile, the broader community remains focused on the intense competitive landscape between LLY and Novo Nordisk, closely monitoring pricing strategies, new drug delivery formats, and ongoing regulatory scrutiny regarding the compounded weight-loss drug market.

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. Its pipeline includes CAN-2409 and CAN-3110. The company was founded by Estuardo Aguilar-Cordova in 2002 and is headquartered in Needham, MA.

Candel Therapeutics Inc

Candel Therapeutics is trending as investors react to a significant insider purchase of 550,458 shares and a completed capital raise, which the community views as a major vote of confidence in the company's clinical trajectory. Sentiment is currently divided between long-term holders focusing on upcoming Phase 3 milestones and BLA filings, and skeptics who remain concerned about the impact of dilution on shareholder value.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing active community discussion as traders monitor potential buyout interest and growth prospects for its MS therapy, BRIUMVI, ahead of the company's upcoming earnings call. Investors are focused on the firm's revenue trajectory, recent long-term clinical data, and the potential impact of share repurchases on stock performance.

New Era Energy & Digital, Inc. is an exploration and production company, which engages in selling oil and natural gas products. The company was founded on February 6, 2023 and is headquartered in Midland, TX.

New Era Energy & Digital Inc.

New Era Energy & Digital Inc. is trending as investors monitor the appointment of a new CFO and anticipate the potential announcement of a major hyperscaler tenant. While some community members remain skeptical of management's communication and deal timelines, others are optimistic that the company's behind-the-meter energy model will drive significant long-term growth as infrastructure demand for AI continues to rise.

Greenwich LifeSciences, Inc. engages in the development of a breast cancer immunotherapy designed to prevent the recurrence of breast cancer following surgery. The company was founded by Eric Rothe on August 29, 2006 and is headquartered in Stafford, TX.

Greenwich LifeSciences Inc

Greenwich LifeSciences is trending due to a preliminary update from its Phase 3 FLAMINGO-01 trial, which revealed an exceptionally low recurrence rate of less than 1% per year in the open-label arm. Investors are heavily discussing the significance of these consistent long-term results, with the community actively speculating on upcoming abstract titles for the AACR annual meeting and potential strategic partnerships or buyouts.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is trending as investors react to a significant settlement regarding patent litigation, a move that removes a long-standing legal overhang and shifts market focus toward the company's robust oncology pipeline and combination vaccine potential. Community discussion is heavily focused on the stock's high short interest and the potential for a major strategic partnership or buyout to accelerate future growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026

PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 30, 2026 PAVmed to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and...

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026

Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026 Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update...

What's Going On With PAVmed Shares Thursday?

PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diagnostics secured a contractread more...

Why Is PAVmed Stock Skyrocketing Wednesday?

PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for its cancer prevention test.read more...

<ul class="summary-bullets"><li>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing.</li><li>The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.</li><li>Trading in PAVM shares was halted at 09:58 ET.</li></ul>Shares of PAVmed Inc. (PAVM) jumped more than 250% on Wednesday morning after its subsidiary, Lucid Diagnostics Inc. (LUCD), won a contract from the U.S. Department of Veterans Affairs (VA) to supply its EsoGuard Esophageal DNA Test for detecting esophageal precancer across the VA healthcare system.The agreement provides more than nine million enrolled veterans access to&nbsp;esophageal&nbsp;precancer testing.<a href="https://stocktwits.com/symbol/PAVM">PAVM</a> was among the top trending tickers on Stocktwits at the time of writing. <a href="https://stocktwits.com/symbol/LUCD">LUCD</a> shares jumped 23% to their highest levels since May 2025.<h2 class="st-heading-2">Contract Details</h2>The contract is issued under the VA Federal Supply Schedule and includes pre-negotiated pricing that aligns with the Medicare reimbursement rate set by the Centers for Medicare &amp; Medicaid Services. This structure allows VA hospitals and clinics nationwide to procure EsoGuard through a single, standardized framework.“The VA operates at significant clinical and operational scale, and selection by a healthcare system of this size reflects the strength of the clinical evidence supporting EsoGuard,” said Shaun O'Neil, President and Chief Operating Officer of Lucid Diagnostics.&nbsp;&nbsp;Lucid Diagnostics focuses on early cancer prevention diagnostics, particularly for patients with gastroesophageal reflux disease who face an elevated risk of developing esophageal precancer and cancer.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment for PAVM on Stocktwits flipped to ‘extremely bullish’ from ‘bearish’ a day earlier, accompanied by ‘extremely high’ message volumes.<figure class="image"><img src="https://news.stocktwits-cdn.com/PAVMED_jpg_a10dfa8673.webp" alt="PAVMED.jpg" width="925" height="96"><figcaption>PAVM's Sentiment Meter and Message Volumes at 10:20 a.m. ET on Jan. 21, 2026 | Source: Stocktwits</figcaption></figure>Sentiment for LUCD changed to ‘bullish’ from ‘neutral’ a day earlier, while message volumes were ‘extremely high’.One user believes the news has ‘real value’.<stembedurl>https://stocktwits.com/pow7904/message/642397455</stembedurl>PAVmed implemented a 1-for-30 reverse stock split on January 2.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/gold-rises-to-record-highs-as-investors-seek-out-safe-haven-assets/cmUDMEjR4fK">Gold Jumps To All-Time Highs – Veteran trader Peter Brandt Says $8,000 An Ounce Is On The Cards</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs?

PAVM Stock - The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

Equity

The company’s subsidiary, Lucid Diagnostics, secured a contract from the U.S. Department of Veterans Affairs to provide its EsoGuard Esophageal DNA Test for the detection of esophageal precancer.

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard

Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard Lucid Diagnostics Awarded U.S. Department of Veterans Affairs Contract for EsoGuard PR Newswire NEW YORK, Jan. 21...

PAVmed Announces Reverse Stock Split

PAVmed Announces Reverse Stock Split PAVmed Announces Reverse Stock Split PR Newswire NEW YORK, Dec. 30, 2025 NEW YORK, Dec. 30, 2025 /PRNewswire/ --PAVmed Inc.(NASDAQ: PAVM) ('PAVmed' or the...

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection

Lucid Diagnostics Announces Positive Data from the Largest Reported Real-World Experience of Esophageal Precancer Detection Lucid Diagnostics Announces Positive Data from the Largest Reported...

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree

Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree Lucid Diagnostics Named a GenomeWeb 2025 Best Places to Work Top-Ranking Honoree PR Newswire NEW YORK, Nov. 20, 2025...

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum

Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and...

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVM
PAVmed Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest PAVM News

PAVMPAVmed Inc